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The phosphatidylinositol 3-kinase/Akt pathway is responsible for key aspects of tumor progression,
and is frequently hyperactivated in cancer. We have recently identiﬁed palladin, an actin-bundling
protein that functions to control the actin cytoskeleton, as an Akt1-speciﬁc substrate that inhibits
breast cancer cell migration. Here we have identiﬁed a role for Akt isoforms in the regulation of
palladin expression. Akt2, but not Akt1, enhances palladin expression by maintaining protein stabil-
ity and upregulating transcription. These data reveal that Akt signaling regulates the stability of
palladin, and further supports the notion that Akt isoforms have distinct and speciﬁc roles in
tumorigenesis.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Palladin is an actin-bundling protein and plays an important
role in organization of the actin cytoskeleton [1]. It also acts as a
molecular scaffold by linking actin to a number of anchor proteins
including a-actinin [2], Eps8 [3], ezrin [4], proﬁlin [5] and VASP [6].
Short hairpin RNA (shRNA) silencing and knockout mouse studies
have demonstrated a critical role for palladin in stabilizing actin
stress ﬁbers [7–9]. Accordingly, palladin has been shown to en-
hance migration of smooth muscle cells [10] and ﬁbroblasts [8].
On the other hand, our recent studies have shown that palladin
has anti-migratory and anti-invasive functions in breast carcinoma
cells [9]. Given that palladin is a key regulator in the establishment
of cell morphology and motility, it is important to dissect regula-
tory mechanisms for palladin.
Palladin is widely expressed in both epithelial and mesenchy-
mal cells [2,7]. Its expression is tightly regulated in various physi-
ological settings. For example, palladin is upregulated during
differentiation of myoﬁbroblasts [11] and dendritic cells [4]. Palla-
din expression is also increased in response to signals induced by
vascular injury and smooth muscle cell hypertrophy [10]. In
addition to these physiological functions, recent studies have indi-
cated a role for palladin in human carcinomas. Overexpression ofchemical Societies. Published by E
hosphatidylinositol 3-kinase;
al bovine serum; WT, wild-
hin).palladin is observed in breast carcinoma tissues [12] as well as tu-
mor-associated ﬁbroblasts of pancreatic adenocarinomas [13]. In-
deed, palladin has been proposed as a prognostic biomarker in
solid tumors. However, the molecular mechanisms that regulate
the expression and activity of palladin have remained elusive. Pall-
adin is phosphorylated on tyrosine residues in cells expressing ac-
tive Src, but the kinase that is responsible for the phosphorylation
and the functional signiﬁcance of tyrosine phosphorylation remain
to be determined [14].
The expression of Akt isoforms is also frequently deregulated in
breast carcinomas [15,16]. Hyperactivation of the phosphatidylin-
ositol 3-kinase (PI 3-K)/Akt pathway enhances tumor growth and
survival, thereby making Akt an attractive target for the develop-
ment of anti-cancer therapeutics [17,18]. Recent studies have dem-
onstrated that Akt1 and Akt2 have opposing functions in breast
cancer cell migration and metastasis [19–24]. There is little infor-
mation, however, on the isoform-speciﬁc downstream substrates
of Akt. We have recently identiﬁed palladin as an Akt1-speciﬁc
substrate that inhibits breast cancer cell migration [9]. Phosphory-
lation of palladin at Ser507 by Akt1 promotes the formation of ac-
tin bundles and in turn reduces both random and directional
migration. These studies provide a link between Akt isoform-spe-
ciﬁc signaling and cytoskeleton rearrangement. Given the diagnos-
tic and therapeutic implications of palladin and Akt in cancer
progression, the present study was undertaken to investigate if
Akt isoforms differentially regulate the expression and stability
of palladin in breast tumor cells. Here we show that Akt2, but
not Akt1, regulates palladin expression by promoting protein sta-
bility and upregulation of mRNA levels.lsevier B.V. All rights reserved.
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2.1. Cell lines and reagents
HEK293T, HeLa, MCF7 and MDA-MB-231 cells were maintained
in Dulbecco’s Modiﬁed Eagle Medium (DMEM) (Cellgro; Manassas,
VA) supplemented with 10% fetal bovine serum (HyClone; Wal-
tham, MA). MCF10A were grown in DMEM/Ham’s F12 medium
supplemented with 5% equine serum (Gibco-brl; Carlsbad, CA),Fig. 1. Akt signaling pathway regulates palladin expression. HeLa cells were treated
with LY294002 (10 lM) (A) or SN30978 (5 lM) (B) for the indicated times. Protein
levels of palladin were analyzed by immunoblotting with the indicated antibodies.
Palladin expression levels were quantiﬁed and shown as a ratio compared to
control. Asterisk (*) indicates a non-speciﬁc band.
Fig. 2. Expression levels of palladin are differentially regulated by Akt isoforms. (A) MDA-
Akt2 shRNA sequence 1, or empty vector for 48 h. Lysates were subjected to immunoblot
1 or sequence 2, or empty vector for 72 h. Cell extracts were immunoblotted with the ind
sequence 2 or empty vector for 72 h. Protein levels of palladin were detected as described
control. Asterisk (*) indicates a non-speciﬁc band. The multiple bands of palladin are fu
observed previously [3].10 lg/ml insulin (Sigma–Aldrich; St. Louis, MO), 500 ng/ml hydro-
cortisone (Sigma–Aldrich), 20 ng/ml EGF (R&D systems; Minneap-
olis, MN) and 100 ng/ml cholera toxin (List Biological Labs;
Campbell, CA). LY294002 (Alexis Biochemicals; Farmingdale, NY)
and SN30978 (referred to Akti-1/2 in [25]; gift from Dr. Peter Shep-
herd (Symansis and University of Auckland, New Zealand)) were
added to cells at ﬁnal concentrations of 10 and 5 lM, respectively.
MG132 (Sigma–Aldrich) and cycloheximide (Sigma–Aldrich) were
added to cells at 10 lM and 20 lg/ml, respectively. Anti-Akt1
monoclonal antibody, anti-Akt2 polyclonal antibody and anti-
phospho-Akt S473 (pAkt) monoclonal antibody were obtained
from Cell Signaling Technology (Danvers, MA). Anti-Akt polyclonal
antibody was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Anti-palladin polyclonal antibody was from ProteinTech
Group (Chicago, IL). Anti-ERK monoclonal antibody was from BD
Transduction (Lexington, KY). Horseradish peroxidase-conjugated
anti-mouse and anti-rabbit immunoglobulin G (IgG) antibody were
purchased from Chemicon (Billerica, MA). Anti–actin monoclonal
antibody was purchased from Sigma–Aldrich. Anti-Akt1 polyclonal
antibody was raised against a synthetic peptide (VDSERRPHFPQF-
SYSASGTA) and generated in house. Anti-HA monoclonal antibody
was puriﬁed from the 12CA5 hybridoma.
2.2. Plasmids
HA-Palladin plasmid was a gift from Dr. Mikko Ronty [14] (Uni-
versity of Helsinki, Finland). HA-Palladin S507A has been describedMB-231, MCF7 and MCF10A cells were infected with Akt1 shRNA sequence 1 and/or
analysis. (B) MDA-MB-231 and MCF7 cells were infected with Akt1 shRNA sequence
icated antibodies. (C) MDA-MB-231 and MCF7 cells were infected with Akt2 shRNA
in (B). Palladin expression levels were quantiﬁed and shown as a ratio compared to
lly consistent with different posttranslational modiﬁcation patterns of palladin, as
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mutagenesis with the following primers: sense, 50-CTCATGTCAGAA
GGCCTCGTTCTAGAGATAGGGACAGTGGAGAC-30; anti-sense, 50-GT
CTCCACTGTCCCTATCTCTAGAACGAGGCCTTCTGACATGAG-30. HA-
Palladin S507E was constructed by site-directed mutagenesis with
the following primers: sense, 50-CTCATGTCAGAAGGCCTCGTTCTA
GAGAGAGGGACAGTGGAGAC-30; anti-sense, 50-GTCTCCACTGTCCC
TCTCTCTAGAACGAGGCCTTCTGACATGAG-30. All sequences were
veriﬁed by DNA sequencing.
2.3. RNA interference
Akt1 shRNA sequence 1 and Akt2 shRNA sequence 1 have been
described previously [9]. Akt1 shRNA sequence 2 and Akt2 shRNA
sequence 2 were cloned into the pLKO lentiviral expression system
as previously described [9]. Akt1 shRNA sequence 2: sense, 50-CC
GGgctacttcctcctcaagaatgCTCGAGcattcttgaggaggaagtagcTTTTTG-30;
anti-sense, 50-AATTCAAAAAgctacttcctcctcaagaatgCTCGAGcattc ttga
ggaggaagtagc-30. Akt2 shRNA sequence 2: sense, 50-CCGGcttc gacta
tctcaaactcctCT CGAGaggagtttgagatagtcgaagTTTTTG-30; anti-sense,
50–AATTCAAAA ActtcgactatctcaaactcctCTCGAGaggagtttgagatagtc-
gaag-30.
2.4. Immunoblots and quantitative real-time RT-PCR
Immunoblotting was performed as described previously [9].
Protein levels were quantiﬁed with ImageJ from NIH software.
Total RNA was isolated with Trizol (Invitrogen, Camarillo, CA)
according to the manufacturer’s protocols. Reverse transcription
was performed using random hexamers and multiscribe reverseFig. 3. Phosphorylation of palladin at Ser507 does not regulate its expression levels. (A) M
palladin Ser507Ala (S507A), HA-palladin Ser507Asp (S507D) or control vector for 24 h. C
and immunoblotting. (B) HeLa cells transfected with HA-palladin WT, S507A or S507D m
Protein levels of palladin were analyzed by immunoblotting with anti-HA antibody. Paltranscriptase (Applied Biosystems, Foster City, CA). Quantitative
real-time PCR was performed using an ABI Prism 7700 sequence
detector (Applied Biosystems). Palladin primers [13]: sense, 50-
AACCGAGCAGGACAGAAC-30; anti-sense, 50-TGGTGGCACTCCCAA-
TAC-30. PCR reactions were carried out in triplicates. Quantiﬁcation
of palladin expression was calculated by the dCT method with
GAPDH as the reference gene.
3. Results
3.1. Akt isoforms differentially regulate the expression levels of
palladin
To investigate whether the Akt signaling pathway regulates
palladin protein levels, HeLa cells were treated with the PI 3-K
inhibitor LY294002. LY294002 efﬁciently inhibits phosphorylation
of Akt (Fig. 1A). Notably, expression of palladin is decreased by
LY294002 treatment in a time-dependent manner. On the other
hand, expression of an unrelated protein ERK is not affected. Pall-
adin expression is also reduced in cells treated with the Akt inhib-
itor SN30978 [25] (Fig. 1B). The speciﬁcity of the palladin antibody
has been tested in different cell lines using palladin shRNA (Fig. S1
[9]). These ﬁndings indicate that Akt selectively modulates the
expression levels of palladin.
We next determined if Akt isoforms have differential roles in
the regulation of palladin expression, and used shRNA targeting
Akt1 or Akt2. In MDA-MB-231 and MCF7 breast cancer cell lines
as well as immortalized non-tumorigenic MCF10A breast epithelial
cells, knockdown of Akt2 reduces palladin expression by more than
50% (Fig. 2A). Conversely, depletion of Akt1 has no effect.DA-MB-231 and HeLa cells were transfected with wild-type (WT) HA-palladin, HA-
ells were then treated with LY294002 (10 lM) or DMSO for 24 h before harvesting
utants were treated with cycloheximide (CHX; 20 lg/ml) for the indicated times.
ladin expression levels were quantiﬁed and shown as a ratio compared to control.
Fig. 4. Akt2 regulates the stability as well as mRNA expression levels of palladin. (A) HeLa cells were treated with LY294002 (10 lM) or DMSO for 12 h. Six hours before
harvesting, cells were treated with MG132 (10 lM) or DMSO. Lysates were subjected to immunoblotting. (B) MDA-MB-231 and HeLa cells were treated with LY294002
(10 lM) or DMSO for the indicated times. MG132 (10 lM) or DMSO was added to cells for 6 h before harvesting. Levels of palladin expression were analyzed by
immunoblotting . (C) HeLa cells transfected with HA-palladin were infected with Akt1 shRNA sequence 1 or Akt2 shRNA sequence 1, or empty vector for 72 h. Sixteen hours
before harvesting, cells were treated with MG132 (10 lM) or DMSO. Lysates were immunoblotted. (D) MDA-MB-231 and MCF10A cells were treated with SN30978 (5 lM) or
DMSO for 12 h. mRNA levels of palladin were analyzed by quantitative real-time RT-PCR. The levels of palladin mRNA are expressed as a ratio relative to the GAPDH mRNA in
each sample. Protein expressions were analyzed by immunoblotting. (E) MDA-MB-231 and MCF10A cells were infected with Akt1 shRNA sequence 1, Akt2 shRNA sequence 1,
or empty vector for 48 h. mRNA and protein levels of palladin were analyzed as described in (D). Palladin expression levels were quantiﬁed and shown as a ratio compared to
control. Asterisk (*) indicates a non-speciﬁc band. # And ## indicates a P-value of <0.05 and <0.01, respectively.
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similar results (Fig. 2B and C). These results demonstrate that pall-
adin expression is regulated by Akt2, but not Akt1.
3.2. Palladin expression is not regulated by phosphorylation at Ser507
We have recently shown that palladin is an Akt1-speciﬁc sub-
strate [9]. Since the expression levels of palladin are not affected
by Akt1, we hypothesized that phosphorylation of palladin atSer507 does not play a role in its expression or stability. To test
this, MDA-MB-231 and HeLa cells were transfected with wild-type
(WT) palladin, a non-phosphorylatable Ser507Ala mutant, or a
phosphomimetic Ser507Asp mutant, followed by LY294002 treat-
ment. As predicted, LY294002 attenuates the expression of WT
and mutant palladin alleles to a similar extent (Fig. 3A). In addition
to the Ser507Asp mutant, a Ser507Glu phosphomimetic mutant of
palladin was also generated. The effect of LY294002 on the Ser507-
Glu allele is very similar to that of WT palladin (data not shown),
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phorylation status. To further investigate the role of palladin phos-
phorylation in protein stability, de novo protein synthesis was
inhibited by treating cells with cycloheximide. The degradation
rates of WT palladin and the mutants are similar (Fig. 3B), again
indicating that palladin phosphorylation at Ser507 does not regu-
late stability. These data are in agreement with the model that
Akt isoforms differentially regulate the function and expression
of palladin: Akt1 modulates the activity of palladin by phosphory-
lating it at Ser507, whereas Akt2 regulates palladin protein expres-
sion and stability.
3.3. Akt2 promotes the stability of palladin and enhances its mRNA
expression
Akt2 could modulate palladin levels by regulating its synthesis
and/or degradation. To test these possibilities, we ﬁrst determined
if Akt signaling stabilizes palladin protein, by treating cells with
the proteasome inhibitor MG132. As shown in Fig. 4A, MG132 efﬁ-
ciently protects palladin from LY294002-induced degradation. We
then performed a time-course assay, in which MDA-MB-231 and
HeLa cells were incubated with LY294002 for various times, fol-
lowed by treatment with MG132. At all time points examined, sta-
bilization of palladin was observed in the presence of MG132
(Fig. 4B). Using an shRNA approach, our results show that in
DMSO-treated cells, palladin expression levels are decreased by
40% in the presence of Akt2 shRNA (pLKO: 1.0; Akt2 shRNA: 0.6)
(Fig. 4C). In contrast, in MG132-treated cells, Akt2 knockdown only
decreases palladin expression levels by 10% (pLKO: 3.0; Akt2
shRNA: 2.7). These data demonstrate that the reduction of palladin
expression in Akt2 shRNA-expressing cells is at least partially re-
versed by MG132 treatment. Real-time RT-PCR analysis shows that
whereas treatment of cells with Akt inhibitor SN30978 reduces
palladin protein levels, there is no detectable effect on mRNA levels
(Fig. 4D). Thus, Akt2 regulates palladin expression, at least in part,
by promoting its stability. Interestingly, when cells are depleted
with Akt2 for more than 24 h, both the protein and mRNA levels
of palladin are signiﬁcantly reduced (Fig. 4E). Taken together, these
results suggest that Akt2 regulates palladin expression by
maintaining protein stability as well as enhancing transcription.4. Discussion
Although the key role of Akt in tumor initiation and progression
is well established, isoform-speciﬁc signaling of Akt has remained
less well studied. The present study shows that expression of pall-
adin in breast cancer cells is regulated by an Akt2, but not Akt1,
pathway. We further show that Akt2 enhances palladin expression
by maintaining its stability as well as upregulating mRNA expres-
sion. Since phosphorylation of proteins is commonly involved in
the modulation of protein stability [26], we tested if Akt1-medi-
ated phosphorylation of palladin regulates its stability. Our ﬁnding
that neither the phosphomimetic nor non-phosphorylatable mu-
tants of palladin have altered degradation rates compared to the
WT protein indicates that phosphorylation of palladin does not
play a role in its stability. Together with our previous observations,
our results suggest that the activity and expression of palladin are
regulated by distinct Akt isoforms; whereas Akt1 plays a critical
role in the inhibition of breast cancer cell migration by phosphor-
ylating palladin, Akt2 upregulates the expression of palladin.
The mechanism by which Akt2 enhances the mRNA expression
of palladin is not known at the present time. Akt has been shown to
directly phosphorylate transcription factors such as FOXO, as well
as proteins that play critical roles in the transcription process such
as glycogen synthase kinase-3b [26]. However, to date none ofthese have been demonstrated to be isoform-speciﬁc. MDM2, an
E3 ubiquitin-protein ligase which mediates degradation of the
transcription factor p53, is phosphorylated speciﬁcally by Akt2
[27]. It will be interesting to examine if this Akt2 substrate plays
a role in palladin transcription. Our results which reveal that
Akt2 promotes palladin stability are somewhat surprising, since
our previous studies showed that palladin associates with Akt1,
but not Akt2 [9]. It is possible that the interaction between palladin
and Akt2 is too weak to be detected in our experimental system.
Alternatively, Akt2 may modulate a downstream protein, which
in turn protects palladin from degradation.
It is known that in human carcinoma cells, both the stimulatory
and inhibitory proteins of the actin cytoskeleton are coordinately
upregulated [28]. Indeed, increased expression of palladin is ob-
served in human breast tumor samples [12] and rat invasive mam-
mary carcinoma cells [28]. Given its molecular scaffolding role,
overexpression of palladin may cause an imbalance of its interact-
ing proteins that remodel the cellular architecture. Alternatively,
nuclear expression of palladin is observed in multiple cell types
[13,29], rising the possibility that palladin has a function in the
regulation of gene expression. The clinical relevance of palladin
and Akt deregulation in carcinoma cells is highlighted by the fact
that increased Akt1 expression is found in both estrogen-receptor
(ER)-positive and ER-negative breast tumors. In contrast, overex-
pression of Akt2 is more frequently observed in ER-negative breast
tumors [30]. Whether there is a correlation between Akt2, palladin
and ER expression in breast cancer patients remains to be deter-
mined. Currently, seven palladin isoforms, which arise from alter-
native start sites or splicing, have been identiﬁed in humans [13].
Our study focuses on the regulation of the most widely-expressed
isoform (90 kDa) of palladin by the Akt pathway. Our results also
indicate that Akt2 regulates the expression of another major iso-
form (140 kDa) of palladin (data not shown). It would be interest-
ing to test if Akt signaling modulates the expression levels of other
palladin isoforms.
Taken together, we present evidence on a signaling pathway
that regulates the stability of palladin. This study further highlights
the importance of Akt isoform-speciﬁc signaling in breast cancer,
which is predicted to have important ramiﬁcations for the develop-
ment of anti-cancer drugs targeting the Akt pathway.
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